|
AVINZA Co-Promotion (Details) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended |
|---|---|
|
Mar. 31, 2013
|
|
| Summary of co-promote termination liability | |
| Net present value of payments based on estimated future net Avinza product sales as of December 31, 2012 | $ 12,534 |
| Assumed payments made by Pfizer or assignee | (853) |
| Fair value adjustments | 492 |
| Total co-promote termination liability as of March 31, 2013 | 12,173 |
| Less: current portion of co-promote termination liability as of March 31, 2013 | 4,257 |
| Long-term portion of co-promote termination liability as of March 31, 2013 | $ 7,916 |